Page last updated: 2024-11-12
ottelione a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
ottelione A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10946837 |
| CHEMBL ID | 2204311 |
| SCHEMBL ID | 10136107 |
| MeSH ID | M0443028 |
Synonyms (5)
| Synonym |
|---|
| ottelione a |
| rac-ottelione a |
| CHEMBL2204311 |
| SCHEMBL10136107 |
| (1s,3s,3ar,7as)-1-ethenyl-3-[(3-hydroxy-4-methoxyphenyl)methyl]-7-methylidene-2,3,3a,7a-tetrahydro-1h-inden-4-one |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (8)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID712847 | Antiproliferative activity against human NCI-H460 cells assessed as cell viability after 72 hrs by CellTiter96 assay | 2012 | ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12 | Synthesis and antiproliferative activities of ottelione a analogues. |
| AID712849 | Antiproliferative activity against human KB cells assessed as cell viability after 72 hrs by CellTiter96 assay | 2012 | ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12 | Synthesis and antiproliferative activities of ottelione a analogues. |
| AID712844 | Antiproliferative activity against human COLO205 cells assessed as cell viability after 72 hrs by CellTiter96 assay | 2012 | ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12 | Synthesis and antiproliferative activities of ottelione a analogues. |
| AID712848 | Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by CellTiter96 assay | 2012 | ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12 | Synthesis and antiproliferative activities of ottelione a analogues. |
| AID712842 | Inhibition of pig neuronal tubulin polymerization at 10 uM by fluorescence analysis | 2012 | ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12 | Synthesis and antiproliferative activities of ottelione a analogues. |
| AID712846 | Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by CellTiter96 assay | 2012 | ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12 | Synthesis and antiproliferative activities of ottelione a analogues. |
| AID712845 | Antiproliferative activity against human A375 cells assessed as cell viability after 72 hrs by CellTiter96 assay | 2012 | ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12 | Synthesis and antiproliferative activities of ottelione a analogues. |
| AID712843 | Displacement of [3H]colchicine from tubulin in pig brain at 10 uM after 16 hrs by scintillation proximity assay | 2012 | ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12 | Synthesis and antiproliferative activities of ottelione a analogues. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.91
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.91) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (9.09%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (90.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||